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Abstract
We analyzed prevalence, risk factors and hepatitis 
C virus (HCV) genotype distribution in different 
population groups in Croatia in the context of HCV 
epidemiology in Europe, with the aim to gather all 
existing information on HCV infection in Croatia which 
will be used to advise upon preventive measures. It is 
estimated that 35000-45000 of the Croatian population 
is chronically infected with HCV. Like in other European 
countries, there have been changes in the HCV 
epidemiology in Croatia over the past few decades. 
In some risk groups (polytransfused and hemodialysis 
patients), a significant decrease in the HCV prevalence 
was observed after the introduction of routine HCV 
screening of blood/blood products in 1992. Injecting 
drug users (IDUs) still represent a group with the 
highest risk for HCV infection with prevalence ranging 
from 29% to 65%. Compared to the prevalence in the 
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Croatian general population (0.9%), higher prevalence 
rates were found in prison populations (8.3%-44%), 
human immunodeficiency virus-infected patients (15%), 
persons with high-risk sexual behavior (4.6%) and 
alcohol abusers (2.4%). Low/very low prevalence was 
reported in children and adolescents (0.3%) as well as 
in blood donors (0%-0.009%). In addition, distribution 
of HCV genotypes has changed due to different routes 
of transmission. In the general population, genotypes 
1 and 3 are most widely distributed (60.4%-79.8% 
and 12.9%-47.9%, respectively). The similar genotype 
distribution is found in groups with high-risk sexual 
behavior. Genotype 3 is predominant in Croatian 
IDUs (60.5%-83.9%) while in the prison population 
genotypes 3 and 1 are equally distributed (52.4% 
and 47.6%). Data on HCV prevalence and risk factors 
for transmission are useful for implementation of 
preventive measures and HCV screening.
Key words: Hepatitis C; Seroprevalence; Genotypes; 
Croatia; Europe
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Core tip: As in other European countries, epidemiology 
of hepatitis C has changed in Croatia in last few 
decades. In addition, changes in the hepatitis C virus 
(HCV) genotype distribution were observed due to 
changes in prevailing routes of transmission. Although 
a decline in HCV prevalence was observed in some risk 
groups (polytransfused and hemodialysis patients), 
HCV prevalence is still high in injecting drug users 
(IDUs) (29%-65%), reaching 100% in older injectors 
and those reporting sharing injection equipment. In 
addition, a high HCV prevalence (8.3%-44%) was 
found in Croatian prisoners reflecting high proportion of 
IDUs within this population group. Since IDUs represent 
a group with the highest risk for HCV, strategies to 
reduce risk among IDUs should be considered.
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Barbic L, Stevanovic V, Vranes J. Epidemiology of hepatitis C 
in Croatia in the European context. World J Gastroenterol 2015; 
21(32): 9476-9493  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i32/9476.htm  DOI: http://dx.doi.
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INTRODUCTION
Hepatitis C virus (HCV) represents a major public 
health problem. The World Health Organization (WHO) 
estimates that about 2.8% or 170 million of world’s 
population has been infected with HCV, of whom 15 
million people live in the WHO European region. In 
addition, 86000 hepatitis C-related deaths are reported 
per year in Europe[1]. The HCV prevalence varies 
markedly in different regions and populations. Injecting 
drug users (IDUs) and recipients of blood transfusions 
prior to 1992 are traditionally identified risk groups for 
HCV infection[2-4]. Variable HCV prevalence is reported 
in hemodialysis patients and prison populations[5-11]. 
Transmission of HCV also occurs through occupational, 
perinatal and sexual exposures[12-14]. However, the 
association between HCV transmission and high-risk 
sexual behavior is still controversial[15-17]. Tattooing 
has emerged in recent years as an additional route 
of HCV transmission[18,19]. In addition, some other 
unconventional risk factors for HCV transmission 
such as digestive endoscopy, abortions, acupuncture, 
beauty treatments, practice of contact sports and 
professional pedicure/manicure have been identified 
among HCV-seropositive persons[20].
In this review, the prevalence, risk factors and 
HCV genotype distribution in different population 
groups in Croatia were analyzed in the context of HCV 
epidemiology in Europe (Table 1). 
HCV PREVALENCE AND TRANSMISSION 
RISK FACTORS IN CROATIA
It is estimated that between 35000 and 45000 of 
the Croatian population is chronically infected with 
HCV[21,22]. Prevalence of HCV infection in different 
population groups is presented in Figure 1. 
Polytransfused patients and plasma product recipients
Before the introduction of routine HCV screening of 
blood/blood products in 1992, transfusion-associated 
HCV infections were common in Croatia. A study 
on 359 hemophilia patients in the period from 1993 
to 1999 showed that 75.9% tested positive to anti-
HCV antibodies, of whom all were infected through 
coagulation factor concentrates before 1990[23]. In 
a pilot study conducted in 1992, serologic evidence 
of HCV infection was found in 24.1% polytransfu-
sed patients[24]. With the current blood transfusion 
safety and the availability of recombinant clotting 
factors, these patients are no longer at risk for HCV 
infection[25].
Injecting drug users
IDUs represent the most common risk group for 
HCV infection in Croatia. There are several studies 
estimating prevalence of HCV infection among IDUs 
which showed positivity rate from 29% to 65%, 
according to geographical region[26-30]. Seroprevalence 
rates among IDUs in therapeutic communities were 
significantly higher compared to outpatients (60.66% 
vs 41.86%)[28]. Factors associated with an increased 
risk of HCV infection included age, duration of IDU and 
sharing injection equipment. A very high prevalence 
of 100% was observed among older injectors (40-49 
years) compared to 46.5% in younger injectors (20-29 
years)[29]. HCV-positive IDUs started using heroin at 
a significantly younger age than HCV-negative IDUs 
Vilibic-Cavlek T et al . Epidemiology of hepatitis C in Croatia
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Table 1  Prevalence of anti-hepatitis C virus and hepatitis C virus-RNA in different population groups in Europe (2004-2014)
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Study population/country Study area Sample size Anti-HCV HCV RNA Reference
Intravenous drug users 　
   Belgium Limburg, Antwerp   310 66.2%-84.4% - Mathei et al[64], 2005
   Bulgaria Sofia   773 73.90% - Vassilev et al[65], 2006
   Croatia Brod-Posavina County   208 44.60% - Kolovrat et al[28], 2010
   Zadar County   327      59% - Medić et al[27], 2008
   Multicenter     76 51.30% - Vilibic-Cavlek et al[29], 2011
  Zagreb, Rijeka, Split   401 29%-65% - Kolarić et al[26], 2010
   Greece Multicenter - 43.3%-61.3% -   Raptopoulou et al[60], 2011
   Hungary Budapest   215      15% - Gyarmathy et al[66], 2011
   Italy Multicenter 1085 83.20% - Camoni et al[62], 2010
   - 1320 48.10% - Curcio et al[61], 2011
   Multicenter   543 63.90% 68.30% Stroffolini et al[63], 2012
   Lithuania Vilnius   300      80% - Gyarmathi et al[66], 2011
   Luxembourg Nationwide   268 81.30% - Removille et al[67], 2011
   Romania Bucharest     45 88.90% 57.80% Sultana et al[68], 2011 
   Russia St. Petersburg   387 94.60% - Paintsil et al[3], 2009
   Spain Barcelona 1132      88% - Muga et al[2], 2006
   Sweden Stockholm   310 86.50% - Norden et al[58], 2013
   The Netherlands Amsterdam   497      60%      69% Lindenburg et al[59], 2011 
   Rotterdam   452 38.80% - Norden et al[58], 2013
   United Kingdom Multicenter 1058 27%-74% - Hickman et al[69], 2007
Hemodialysis patients
   Albania Tirana     50 16.70%      56% Vila Brunilda et al[79], 2014
   Croatia Zagreb   128    2.30% - Crnjaković-Palmović et al[34], 2005 
   Istria County   157   3.40% - ICIPH[35], 2014
   France Multicenter 4718   7.70% - Saune et al[81], 2011
   Germany Multicenter 1633   5.80% - Kliem et al[83], 2008
   Italy Sicily   320   6.25% - Li Cavoli et al[82], 2011
   Romania Multicenter   174 39.26% - Voiculescu et al[78], 2010
   Serbia Nationwide 5208 12.70% - Djukanovic et al[80], 2012
1Persons with high-risk sexual behavior
   Croatia (MSM, CSW, STD) Multicenter   821   4.60% 73.10% Vilibic-Cavlek et al[17], 2009
      (MSM) Zagreb   360   3.00% - Bozicevic et al[92], 2009
   Estonia (CSW) Tallin   227   7.90% - Uuskula et al[99], 2008
   Italy (CSW) Verona   345   0.90% - Zermiani et al[100], 2012
   Moldova (MSM) Balti, Chisinau   397 1.2%-3.7% - Zohrabyan et al[95], 2013
   Sweden (MSM) Stockholm 1008   0.50% - Blaxhult et al[93], 2013
   United Kingdom (MSM) London 2309   0.65% - Scott et al[94], 2010
      (MSM) London 1121   1.20% - Price et al[91], 2013
      
Prisoners
   Croatia Multicenter   3348   8.30% - Burek et al[37], 2010
Multicenter     190      11% - Vilibic-Cavlek et al[18], 2011
   France Caen     597   4.90% - Verneuil et al[103], 2009
   Nationwide 60975   4.80%      79% Semaille et al[102], 2013
   Multicenter   5957   5.20% - Roux et al[104], 2014
   Hungary Multicenter   4894   4.90% - Treso et al[9], 2012
   Ireland Regional (Northern)   1185   1.10% - Danis et al[113], 2007
   Italy Multicenter     973      38% - Babudieri et al[10], 2005
   Macedonia Prilep, Bitola     200      20% - Jovanovska et al[109], 2014
   Portugal -     445      11% - Barros et al[107], 2008
   Spain Multicenter     370 22.70% - Saiz de la Hoya et al[110], 2011
   United Kingdom Nationwide 10723 24.20% - Kirwan et al[106], 2011
Scotland   5187      19% - Taylor et al[108], 2013
HIV-infected patients
   Croatia Zagreb   120      15% 72.20% Seme et al[38], 2007
   Italy Ancona   440 32.90% - Orsetti et al[118], 2013
   Slovenia Nationwide   356 10.70% 68.40% Seme et al[114], 2009
   Nationwide   579 7.60%      75% Škamperle et al[117], 2014
   Spain Regional (Southern)   520    69%       71% Cifuentes et al[119], 2012
   United Kingdom London 1017 8.90% - Mohsen et al[115], 2005
Alcohol abusers
   Croatia Istria County   167 2.40% - 2ICIPH[35], 2014
   Germany Hamburg   463 5.20% - Schmidt et al[123], 2013
   Spain Salamanca   396 3.53% - Novo-Veleiro et al[126], 2013
Adult general population
   Bulgaria Plovdiv 2211 1.08% - Atanasova et al[136], 2014 
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More recent data from Istria County (2007-2013) 
showed a similar prevalence of 3.2%[35].
Persons with high-risk sexual behavior
Persons with high-risk sexual behavior (persons with 
multiple sexual partners, men who have sex with men-
MSM, commercial sex workers-CSW, persons with a 
history of sexually transmitted diseases-STDs) show 
a higher HCV prevalence (4.6%)[17] compared to the 
Croatian general population (0.9%)[36]. In a multicenter 
study from 7 cities (Zagreb, Split, Rijeka, Zadar, 
Osijek, Slavonski Brod and Dubrovnik) conducted 
during 2003-2006, the highest seroprevalence rate 
(8.5%) was found in patients with a history of STD 
compared to 6.5% in persons with multiple sex 
partners, 4.0% in CSW/clients of CSW and 2.9% in 
MSM. Among STD markers, a prior HBV infection and 
gonorrhea were shown to be risk factors associated 
with higher HCV prevalence. No other factors reflecting 
risky sexual behavior such as sexual orientation and 
number of sexual partners as well as number of risk 
behaviors correlated with HCV seropositivity. HCV-RNA 
and reported a longer history of IDU. Young IDUs were 
found to be at higher risk for HCV infection because of 
their high-risk behavior patterns. They are usually less 
critical toward drugs, less cautious, and more easily 
influenced by others[27]. The frequency of sharing 
injection equipment was the most important risk factor 
for HCV transmission in this risk group[27-29]. The HCV 
seroprevalence rates ranged from 27.3% in IDUs 
who reported sharing needles/syringes occasionally 
to 100% in those who always shared injection 
equipment[29].
Hemodialysis patients
Hemodialysis patients also represent a risk group for 
HCV infection. In a pilot study conducted in 1992, 
44% of hemodialysis patients showed anti-HCV 
antibodies[24]. A similar seropositivity rate (38%) 
was noted in 1994[31]. Two regional surveys from 
north-west Croatia (1997) and north Adriatic Coast 
(2003) reported prevalence rates of 26.1% and 23%, 
respectively[32,33]. A low prevalence (2.3%) was noted 
in 2005 in a Dialysis Center at one Zagreb hospital[34]. 
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   Croatia Primorje-Gorski Kotar 
County
    785 3.70% - Tićac et al[39], 2010
Zagreb     451 2.20% - Serdar et al[40], 2013
   Multicenter   1950 0.90% - Vilibic-Cavlek et al[36], 2014
   France Paris 14416 0.84% - Meffre et al[133], 2010
   Germany Berlin, Frankfurt 28809 2.4%-3.5%     68% Vermehren et al[144], 2012
   Greece Crete     876 2.20% - Drositis et al[145], 2013
   Italy Regional (Southern)   2195 2.60% - Cozzolongo et al[150], 2009
   Kosovo -   1287 0.50% - Quaglio et al[142], 2008
   Latvia Multicenter   1459 2.40% 71.40% Tolmane et al[146], 2011
   Macedonia Skopje   4000 0.40% - Kiprijanovska et al[140], 2013
   The Netherlands Amsterdam   1364 0.60% - Baaten et al[138], 2007
Arnhem, Nijmegen   2200 0.20% - Slavenburg et al[137], 2008
   Norway Oslo - 0.55% - Vik et al[143], 2008
   Poland Multicenter   1652 0.90% - Ganczak et al[135], 2009
   Romania Nationwide 13460 3.23%     91% Gheorghe et al[147], 2010
   Spain Multicenter - 0.6%-1.6% - Munoz-Gamez et al[132], 2013
Pregnant women
   Croatia  Zagreb County     200 0.50% - Vilibic-Cavlek et al[17], 2009
Istria County     930 1.30% - Kucinar et al[41], 2014
   Greece Piraeus 5497 0.80% - Panagopoulos et al[159], 2004
   Poland Warszaw     544 2.02% - Aniszewska et al[161], 2009
   Russia Cheboksary     150     3% - Asratian et al[163], 2009
   Spain Madrid     157     1% - Santiago et al[154], 2012
   Switzerland Multicenter 9057 0.71% - Prasad et al[153], 2007
Healthcare workers
   Bosnia and Herzegovina Tuzla 1699 0.40% 73.40% Ahmetagić et al[50], 2006
   Italy Regional (Central)     733 1.8%-4.7% - Catalani et al[176], 2004
   Poland Warsaw     961 1.70%     19% Slusarczyk et al[175], 2012
Multicenter     414 1.40% - Ganczak et al[135], 2012
Lodz     520 0.80% - Rybacki et al[173], 2013
Blood donors
   Albania Nationwide   52727 0.60% - Durro et al[182], 2010
   Bosnia and Herzegovina Tuzla   16082 0.08% 91.10% Ahmetagić et al[177], 2009
   Croatia Multicenter 155634 0.04% - Grgičević et al[23], 2006
   Multicenter - 0%-0.009% - Transfusion medicine newsletter[44] 
   Italy Regional (South)   17912 0.50% 　 　Sommese et al[181], 2014
1Persons with high-risx sexual behavior: Men who have sex with men-MSM, commercial sex workers-CSW, persons with sexually transmitted diseases-
STD; 2Istria County Institute of Public Health, Pula, Croatia. ICIPH: Istria County Institute of Public Health; HCV: Hepatitis C virus; HIV: Human 
immunodeficiency virus; IDU: Injecting drug users; STDs: Sexually transmitted diseases; CSW: Commercial sex workers; MSM: Men who have sex with 
men. 
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was detected in 73.1% anti-HCV positive persons, but 
was also found in three seronegative cases (“window 
period”)[17]. 
Prison population
Incarcerated persons accounted for 0.4% of a total 
Croatian population, among which IDUs comprise 
about 25%-30%. In a prison population, the overall 
HCV prevalence is reported to be 8.3%-44%[18,26,37]. 
HCV seropositivity in prisons also correlates 
significantly to IDU. HCV infection is most prevalent 
among IDUs (42%-52%) and relatively high among 
highly promiscuous persons (4.9%)[18,37]. Significant 
differences in seropositivity were found in prisoners 
who reported unprotected sexual activity compared 
to prisoners who used condoms (22% vs 4%). A 
history of tattoos was another risk factor associated 
with higher anti-HCV positivity in this population 
group. HCV-infected prisoners were significantly more 
likely to have a history of a tattoo exposure (27%) 
than HCV-uninfected prisoners (8%). However, it is 
not clear whether tattooing is a real risk factor for 
HCV transmission since many of anti-HCV positive 
prisoners reported other potential exposure to HCV 
(sharing injection equipment or risk sexual behavior). 
In addition, higher seroprevalence rates were found 
in prisoners who were unemployed and in those who 
resided in urban areas[18]. 
Human immunodeficiency virus-infected patients
One study addressed HCV prevalence in human 
immunodeficiency virus (HIV)-infected Croatian 
patients. Among 120 patients tested from 1985 to 
2002, 15% were found to be anti-HCV positive and 
72.2% of them were found to be viremic. A significant 
difference in the HCV prevalence was detected among 
blood and sexual exposure risk groups (66.7% 
vs 6.6%) with the highest prevalence reported in 
hemophiliacs (100%) and IDUs (58.3%)[38]. 
Alcohol abusers
Prevalence of HCV in alcohol abusers in Croatia is 
largely unknown. Regional data showed that HCV 
prevalence in alcoholic patients is higher compared 
to the Croatian general population. Among 167 
consecutive samples from alcoholic patients tested at 
the Istria County Institute of Public Health between 
2007 and 2013, four were confirmed positive for HCV 
antibodies (2.4%)[35]. 
General population
Two studies on the HCV prevalence were conducted 
in the Croatian general population. The 2011-2012 
study included adult population undergoing routine 
preoperative check-up from 4/21 counties located in 
the Croatian mainland. Results of the study suggest 
that HCV is uncommon in both urban and rural 
general population. Eighteen of 1930 (0.9%) tested 
participants were found positive to HCV. No difference 
in seropositivity was found between genders and 
age groups[36]. An earlier study (2006-2007) from a 
Primorje-Gorski Kotar County, located on the north 
Adriatic coast, reported anti-HCV prevalence of 3.7% 
using enzyme-linked immunosorbent assay (ELISA). 
Age distribution of HCV-positive cases showed that 
majority of patients belong to the 21-30 age group 
(44%) and 31-40 age group (19%)[39]. Differences in 
the seroprevalence rates among the Croatian general 
population most probably reflect the methodological 
differences (line immunoassay-LIA and ELISA, 
selection of study participants) in these surveys. 
In the period from 2002-2011, occupational 
exposures were monitored in one Zagreb hospital. 
Of 451 source patients, 2.2% were infected with 
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Figure 1  hepatitis C virus seroprevalence among different population groups in Croatia. IDU: Injecting drug users; STDs: Sexually transmitted diseases; CSW: 
Commercial sex workers; MSM: Men who have sex with men. 
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HCV. Majority of accidents were reported at surgical 
departments (63%), followed by departments of 
internal medicine (22.6%), and other departments 
such as dialysis, different laboratories, neurology, 
psychiatry and radiology[40].
Pregnant women
A few Croatian studies addressed HCV prevalence 
in pregnant women. Two regional studies (Zagreb 
County, 2003-2006 and Istria County, 2011-2012) 
showed HCV prevalence rates of 0.5% and 1.3%, 
respectively[17,41]. The Istrian study analyzed risk 
factors and revealed that 83.3% of seropositive 
women reported a history of IDU and 8.3% reported 
a former relationship with an IDU. HCV seropositivity 
increased with age from 0.3% to 3.1%, starting with 
26-30 age group[41]. A prevalence of 49% was found in 
pregnant IDUs from Split region[42]. 
Children and adolescents
There is no published HCV prevalence research 
involving children in Croatia. In a group of 297 children 
and adolescents (up to 18 years) from Istria County 
tested in the period from 2007 to 2014, only one 
(0.3%) showed anti-HCV antibodies on two repeated 
testing. In one 6-mo-old child, anti-HCV antibodies 
were detected at initial testing while at age of 18 mo 
the result was negative (data from the Microbiology 
Service, Istria County Institute of Public Health). 
Mother’s history of IDU was reported in both cases.
Organ/blood donors
Since 2006, the Croatian Institute of Transfusion 
Medicine has been providing mandatory testing of 
organ donors for bloodborne pathogens. Among 
642 organ donor plasma samples tested between 
2006 and 2012, 1.6% were found to be anti-HCV 
positive[43]. Blood donors represent a group with the 
lowest seroprevalence of HCV infection in Croatia. The 
frequency of confirmed positive donors continuously 
declined from 1.38% in 1992 to 0.035% in 1999[23,24], 
and thereafter remained stable. In the last decade 
(2004-2013), the anti-HCV seropositivity is reported to 
be 0%-0.009%)[44]. 
EPIDEMIOLOGY OF HCV INFECTION IN 
CROATIA IN THE CONTEXT OF HCV 
EPIDEMIOLOGY IN EUROPE
Polytransfused patients and plasma product recipients
Hemophilia patients who received clotting factor 
concentrates and recipients of blood transfusion 
before 1990 both represent high-risk groups for HCV 
infection. As expected, patients requiring multiple 
transfusions have a high prevalence of HCV infection. 
The prevalence of HCV among hemophiliacs correlates 
with the amount and type of product transfused. 
Nearly all hemophiliacs exposed to untreated 
commercial clotting factor concentrates before anti-
HCV screening are HCV positive, while among those 
treated with cryoprecipitates, the anti-HCV positivity 
was about 66%[4]. Similar to seroprevalence in other 
European studies (59%-97%)[45-49], a Croatian study 
from 1990s showed a high HCV seropositivity in 
hemophilia patients (75.9%)[23]. Seroprevalence rate 
of 24.1% in Croatian polytransfused patients is within 
the range of the majority other studies (3%-21%)[48-52]. 
With the implementation of mandatory anti-HCV and 
HCV RNA screening of blood/blood donations, the risk 
of transfusion-associated hepatitis C has virtually been 
eliminated[53]. Rare cases of HCV transmission were 
reported from recently infected donors with serum 
HCV RNA level below the detection limit[54,55]. However, 
many European countries are facing the consequences 
of the past epidemic of transfusion-associated 
hepatitis C. In several European studies, patients 
with transfusion-associated HCV infection account 
for 20%-30% of patients older than 50 years with 
advanced chronic hepatitis, cirrhosis and hepatocellular 
carcinoma[25,56,57].
Injecting drug users
IDU is one of the most efficient routes for HCV trans-
mission[4]. The prevalence of HCV infection among 
IDUs varies, although rates are continuously very 
high in most European countries. Recent studies have 
demonstrated HCV seroprevalence of 38.8%-60% 
in the Netherlands[58,59], 43.3%-61.7% in Greece[60], 
48.1%-83.2% in Italy[61-63], 62.6% in Belgium[64], 73% in 
Bulgaria[65], 80% in Lithuania[66], 81.3% in Luxembourg[67], 
86.5% in Sweden[58], 88% in Spain[2], 88.9% in 
Romania[68] and 94.6%-96% in Russia[3,65]. In Croatia, 
there are considerable geographical variations in HCV 
prevalence among IDUs (29%-65%)[26-30] similar to 
those observed in the United Kingdom (24%-74%)[69]. 
The efficiency of IDU in HCV transmission might be due 
to prolonged virus survival in contaminated syringes. 
A study from Doerrbecker et al[70] addressed HCV 
inactivation and stability profiles on inanimate surfaces 
to mimic viral cross-transmissions among IDUs. Viral 
infectivity on inanimate surfaces was detectable in 
the presence of serum for up to five days. Paintsil 
et al[71] analyzed the survival of HCV in syringes and 
the duration of potential infectiousness. The results 
of their study showed that HCV survived for up to 
63 d in high void volume syringes. Besides syringes, 
sharing of drug injection paraphernalia such as drug 
preparation containers, cotton filters and rinse water 
poses a risk of transmitting the HCV[72]. HCV on a 
spoon as cooker can survive temperatures up to 65 ℃, 
confirming that virus survival on cookers could also be 
a potential source of HCV aside from syringes[70]. Other 
notable risk factors associated with increased risk of 
being HCV-infected in IDUs population include older 
age, unemployment, longer history of IDU and higher 
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number of rehabilitation treatment episodes[14,61].
Hemodialysis patients
The prevalence of HCV among hemodialysis patients 
varies widely between geographic areas as well as 
between centers within the same country. In the 
1990s, high prevalence rates (20%-50%) in most 
of European dialysis population were attributed to 
frequent blood transfusions[5-7,73,74]. The introduction of 
sensitive ELISA tests for screening of blood and organ 
donations, use of erythropoietin in treatment of anemia 
and improvement in infection control practices have 
greatly decreased HCV infection among haemodialysis 
patients[25,75]. A European multicenter study suggested 
a decline in HCV seroprevalence among hemodialysis 
patients in majority, but not in all European countries. 
From 1991 to 2000, anti-HCV prevalence decreased 
in France (42% to 30%), Sweden (16% to 9%), Italy 
(28% to 16%), Hungary (26% to 15%) and Belgium 
(13.5% to 6.8%) and tended to decrease in the 
United Kingdom (7% to 3%)[76]. A similar trend was 
observed among hemodialysis patients in Croatia. 
HCV seroprevalence declined from 44% in 1992[24] to 
23% in 2003[33]. More recent regional data showed 
low and stable seroprevalence rates in Croatian 
hemodialysis patients (2.3%-3.2%)[34,35]. There was 
no significant change in Germany (7%-6%) and Spain 
(5%-12%) by 2000[76]. However, another Spanish 
study from Cordoba showed a decrease in the HCV 
prevalence from 24% in 1992 to 9.2% by the end of 
2002[77]. In contrast, Poland showed not only stable, 
but also very high HCV prevalence (42%-44%)[76]. 
In addition, a high prevalence rate was found in 
Romania (39.26%)[78]. Some more recently published 
studies showed prevalences of 16.7% in Albania[79], 
12.7% in Serbia[80], 7.7% in France[81], 6.25% in 
Italy[82] and 5.8% in Germany[83]. The number of blood 
transfusions and the length of time on dialysis are 
the most important risk factors for HCV acquisition 
in hemodialysis patients[83,84]. Additional risks factors 
include IDU and a history of kidney transplantation[84].
Persons with high-risk sexual behavior
The role of sexual transmission in epidemiology of 
HCV infection is still controversial. In the past, sexual 
transmission has been considered a relatively inefficient 
route for HCV transmission. A risk of HCV transmi-
ssion is extremely low among stable monogamous 
heterosexual partners[85,86]. However, the risk for sexual 
partners is significantly higher when the risk factor 
for the index case is IDU[87-89]. In the last decade HCV 
infection has emerged as a STD in some European 
countries, expecially among HIV-positive MSM. A 
recently published Dutch study showed an increase in 
HCV seroprevalence in HIV-positive MSM from 5.6% 
in 1995 to 20.8% in 2008. Chlamydia trachomatis 
infection, IDU, unprotected anal intercourse and older 
age were variables independently associated with HCV 
infection[90]. Another study conducted among British 
MSM showed an overal seroprevalence of 2.1%. The 
prevalence in HIV-negative MSM (1.2%) was higher, 
but not significantly higher, than that in the general 
population (0.67%). However, the prevalence was 
significantly higher in HIV-positive MSM (7.7%). 
Moreover, HCV infection was more common in MSM 
with a history of syphilis than in those without such 
history (12.2% vs 1.7%) and those who reported 
casual unprotected anal intercourse in the previous 
year than in those who did not report such intercourse 
(4.1% vs 1.2%)[91]. Two Croatian studies found 
a higher prevalence in HCV seropositivity in HIV-
negative MSM (2.9% and 3%)[17,92] compared to the 
general population (0.9%)[36] but these diferences did 
not reach statistical significance. Similar findings were 
reported from other European studies among MSM 
that have controlled for IDU (Sweden, the Netherlands, 
United Kingdom, Moldova)[90,91,93-95]. Among Croatian 
persons with high-risk sexual behavior, the highest 
HCV seropositivity rates were detected in patients 
with a history of STD (8.5%) and persons with 
multiple sex partners (6.5%)[17]. Association between 
HCV seroprevalence and multiple sex partners was 
observed in several studies. However, the number of 
partners associated with infection risk varied among 
studies, ranging from one partner in the previous 
month to more than 50 partners in the previous year 
or lifetime[96,97]. In persons with multiple sex partners, 
there is an increased probability of having sex with an 
infectious partner[98]. In Croatian CSW and their clients, 
a prevalence of 4.0% was found. A higher prevalence 
of 7.9% was reported in Estonian CSW[99]. In contrast, 
prevalence of HCV in Italian CSW was as low as 0.9%, 
lower than in the general Italian population. The low 
HCV prevalence reflects the low prevalence of IDU in 
the analyzed cohort[100].
Prison population
Since IDUs constitute a substantial proportion of 
prison population in many European countries, HCV 
prevalence rates among prisoners are higher than 
in the general population[101]. The HCV seropositivity 
is reported to be 4.9% in Hungary[9], 4.8%-5.2% in 
France[102-104], 7%-24.2% in England and Wales[105,106], 
11% in Portugal[107], 19% in Scotland[108], 20% in 
Macedonia[109], 22.7% in Spain[110] and 38% in Italy[10]. 
Different studies showed association between the 
HCV seroprevalence and history of IDU. Among 
prisoners who reported IDU, rates vary from 60.2% 
in Ukrainian[8], 69% in Portugese[107], 74.7% in 
Italian[10] to a high 87% among Danish prisoners[11]. 
In three Croatian studies conducted among prison 
population the seroprevalence ranged from 4.9% ih 
highly promiscuous persons to 52% in IDUs[18,26,37]. 
Some studies suggested that tattooing and piercing 
are risk factors HCV infections, especially those done 
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in nonprofessional settings[19,111]. In contrast, a Dutch 
study showed no evidence for an increased HCV 
seroprevalence among persons with multiple tattoos 
and/or piercings. The authors suggested that this 
might be due to the introduction of hygiene guidelines 
for tattoo and piercing shops in combination with 
the low observed prevalence HCV in the general 
population[112]. Compared to similar studies, the 
prevalence of HCV among prisoners in Northern 
Ireland is lower (1.1%) than in other European 
countries (only 11% of Irish prisoners reported ever 
injected drugs)[113]. 
HIV-infected patients
With the increased life expectancy of HIV-infected 
patients due to highly active antiretroviral therapy, HCV 
has recently emerged as an important pathogen in 
these patients[114]. Prevalence of HIV/HCV coinfection 
varies substantially according to route of transmission. 
About 50%-90% of HIV positive IDUs are co-infected 
with HCV[15,115,116], whereas the co-infection rate in HIV 
positive MSM is 3.5%-7%[89,115]. In Europe, prevalence 
of HIV/HCV coinfection is reported to be 7.6%-10.7% 
in Slovenia[38,117], 8.9% in the United Kingdom[115], 
32.2% in Italy[118] and 58%-69% in Spain[119]. The 
reported prevalence in Croatian HIV-infected patients 
(15%)[38] is within the European range. HIV infection 
appears to adversely affect the outcome of hepatitis C, 
leading to increased viral persistence, higher levels of 
viremia, and accelerated progression of HCV-related 
liver disease[120,121].
Alcohol abusers
It is traditionally assumed that the prevalence of 
HCV infection in alcohol-dependent individuals is 
higher than in the general population, but the modes 
of transmission are not clearly understood[122-124]. 
Higher risk for trauma and accidents requiring blood 
transfusion could be a potential reason for a higher 
HCV prevalence in alcoholics[125]. Additionally, risky 
sexual behavior and IDU could be confounding factors 
for HCV seropositivity in this population[126]. A wide 
range of prevalence has been reported which could 
be related to a different distribution of risk factors 
among studies. Several earlier European studies 
showed prevalence rates of 14% in Sweden[127,128], 
24.3% in Spain[129] and 31.7% in Italy[130]. History 
of IDU was reported by 58%-88.7% Swedish HCV-
positive alcoholic patients. The prevalence of blood 
transfusions, number of hospital admissions, duration 
of alcohol dependence or presence of tattooing were 
not shown to be factors of importance for the HCV 
transmission[127,128].
Two recently published studies showed lower 
prevalence rates. A Spanish study analyzed a total 
of 396 patients with diagnosis of alcohol abuse/
alcohol dependence consecutively attended at the 
alcoholism unit and found 3.53% to have chronic HCV 
infection. Variables independently associated with 
HCV infection were female gender, current or past 
IDU and the presence of alcoholic liver disease[126]. In 
a German study, anti-HCV antibodies were found in 
5.3% alcohol-dependent patients. A history of IDU or 
nonprofessional tattooing emerged as potential risk 
factors[123]. Data from Norway (Oslo County) showed a 
prevalence of 4.4% in alcoholics[131]. HCV prevalence in 
Croatia was reported to be lower (2.4%)[35] compared 
to European data. However, these data are limited to 
a small number of tested subjects and probably do not 
reflect the prevalence of all alcoholic population.
General population
Data from the European countries indicate significant 
variations in HCV seroprevalence, even within the 
same country. It seems that HCV seroprevalence 
in the Croatian adult general population (0.9%)[36] 
echoes the prevalence rates of many European 
countries (Spain 0.6%-1.6%[132], France 0.84%[133], 
Belgium 0.87%[134], Poland 0.9%[135] and Bulgaria 
1.08%[136]. Lower prevalence rates were reported 
in the Netherlands (0.2%-0.6%)[137,138], Sweden 
(0.37%)[139], Macedonia (0.4%)[140], Greece (0.5%)[141], 
Kosovo (0.5%)[142] and Norway (0.55%-0.7%)[131,143]. 
A German study conducted among adult population 
in two metropolitan emergency departments (Berlin, 
Frankfurt) during 2008-2010 found higher prevalence 
rates (2.4% and 3.5%, respectively). Authors 
suggested that a high HCV prevalence may be partly 
explained by the urban study setting as well as the 
fact that high-risk populations such as IDU and 
homeless people were not excluded from the study. 
Additionally, some other risk groups (e.g., patients with 
coagulation disorders or liver transplant candidates) 
may even have been overrepresented which may 
have accounted for selection bias[144]. Similar HCV 
prevalence rates was found in the Cretan (2.2%)[145] 
and the Latvian general population (2.4%)[146]. A high 
overall seroprevalence rate (3.23%) was reported 
in a Romanian nationwide study (2006-2008), with 
significant differences between the main geographical 
regions (2.63%-4.25%) as well as between counties 
(0.56%-7.19%)[147]. Italy has a particular south-to-
north prevalence gradient, with very high prevalence 
in south and central Italy (7.3% and 6.1%) and lower 
in the north (2.6%)[4,148,149].
The majority of European studies showed no 
difference in HCV seropositivity between genders[149,150] 
or a higher prevalence in males[77,146,151]. In contrast, 
a Romanian study has found higher HCV prevalence 
among females (3.51%) compared to males 
(2.85%)[147]. There was no significant difference in the 
HCV seropositivity between males (1.2%) and females 
(0.7%) in the Croatian population[36].
Although in some European regions age-specific 
seroprevalence generally increases with age[76,150,152], 
no difference in HCV prevalence was found among 
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different age groups in Croatia (0.7%-1.7%)[36]. 
Italian authors reported a bimodal distribution of 
HCV with the highest prevalence in subjects over 75 
years of age[149]. Seroprevalence of anti-HCV could 
be considered bimodal in Croatian patients as well, 
with the highest prevalence in the 30-39 age group 
(1.7%)[36].
Pregnant women
Prevalence of HCV in pregnant women is similar to 
that in the general age-matched population. HCV 
seroprevalence in the Croatian pregnant women 
(0.5%-1.3%) is comparable to that reported in 
Switzerland (0.71%)[153] and Spain (1%-1.44%)[154,155]. 
Lower prevalence rates were reported in northern 
Europe (United Kingdom; 0.19%-0.22%[156], Scotland: 
0.3%-0.4%[157]), while Italy, Greece, Poland, Slovakia 
and Russia reported higher HCV seropositivity (1.9%, 
0.8-1.95%, 2.02%, 2.2% and 3%, respectively[158-163]. 
In a Polish study, the most commonly identified risk 
factors were history of blood products transfusion 
before 1992 (24%), hospitalization with surgical 
procedures (23%) and IDU (15%)[161]. In a Croatian 
study, all but one HCV seropositive pregnant women 
reported current or past IDU or a former relationship 
with an IDU (83.3% and 8.3%, respectively)[41]. 
HCV prevalence in Croatian pregnant IDUs (49%)[42] 
is similar to the overall prevalence among IDUs 
(51%)[27,29].
Children and adolescents
Before 1992, the mode of HCV acquisition in children 
was blood transfusion. Higher prevalence rates of 
10%-20% have been reported in children with other 
potential exposures such as hemodialysis, malignancy 
and surgery for congenital heart disease[164-166]. 
The prevalence reported in Croatian children and 
adolescents (0.3%) is within the European range 
(0.05%-0.4%)[167,168]. Vertical (mother-to-child) 
transmission and adolescent high-risk behaviors (IDU) 
are now the major routes of HCV transmission in 
developed countries[169]. The average risk for vertical 
transmission is about 4% per birth[4,14]. Perinatal 
transmission is confined almost always to women with 
detectable HCV RNA[167]. Factors predisposing to HCV 
transmission are higher maternal viral load at the time 
of delivery, maternal history of IDU and untreated HIV 
infection[14]. Breastfeeding carries no further risk of 
HCV transmission[4,170].
Occupationally exposed groups
Occupational HCV transmission has been reported 
among healthcare workers (HCWs) who have 
sustained contaminated needle stick injuries[4]. 
Prevalence studies among HCWs indicate the low 
risk for HCV infection associated with occupational 
exposures. The HCV prevalence among HCWs was not 
found to significantly differ from that of the general 
population[171-173]. However, some differences in the 
prevalence among regions are observed. Very low 
overall HCV prevalences were reported in Bosnian and 
Herzegovinian and Belgian HCWs (0.4% and 0.41%, 
respectively)[50,174]. However, a Belgian study showed 
higher rates in three larger metropolitan hospitals 
(1.3%-2.3%)[174]. Three studies conducted in Poland 
showed prevalence rates 0.8%-1.7%[135,173,175]. Higher 
HCV prevalence was found in Italy. A study conducted 
in Pistoia (central Italy) analyzed samples from 511 
HCWs engaged in direct clinical task and 222 clerical/
nurse school attendees, of whom 3.8% and 1.8% 
were seropositive to HCV[176]. There are no published 
data on the HCV prevalence in the Croatian HCWs.
Blood donors
Blood donors’ studies showed a decreasing trend in 
HCV prevalence across time. Data from European 
countries showed prevalence of 0.13% in Norway[143], 
0.08%-0.26% in Bosnia and Herzegovina[177,178], 
0.16%-0.32% in Germany[179], 0.4% in Hungary[180], 
0.5% in Italy[181], 0.6% in Albania[182] and 0.3%-1.5% 
in Romania[183]. After 2000, HCV seroprevalence in 
Croatian blood donors was continuously very low 
(0.009%-0.03%)[44]. Since blood donors represent a 
strictly controlled group, it is expected that the HCV 
prevalence is lower than in the general population. 
HCV GENOTYPES DISTRIBUTION IN 
CROATIA
HCV RNA was detected in 72.2%-82.7% Croatian HCV 
infected patients[17,32,38]. Prevalence of HCV genotypes 
varies by different population groups (Figure 2) as well 
as by regions. In the general population, genotype 
1 is the most widely distributed (60.4%-79.8%), 
followed by genotype 3 (12.9%-47.9%)[184-186]. The 
most commonly detected subtype is 1b (37.4%)[184]. 
In a 10-year study (1995-2006) conducted in 
four geographical regions (two regions in Croatian 
mainland and two regions located on the Adriatic 
Coast), genotype 1 was predominant in three regions 
(north-west/north-east continental and north coastal 
area) with prevalence rates 60.4%-76.1% while in a 
south coastal area, the prevalence of both genotype 
1 and genotype 3 was similar (46.9% and 47.9%, 
respectively). In other regions, genotype 3 was found 
in 18.3%-32.4% patients[184]. Another study conducted 
in north-east Croatia (2009-2011) detected genotype 
1 in 79.8% and genotype 3 in 12.9% patients[187]. 
The difference in genotype 3 prevalence between 
regions could be attributed to different populations. 
The first study included residents of Split, second 
largest Croatian city with a large number of IDUs in 
whom genotype 3 is the most prevalent. Percentage 
of genotypes 2 and 4 was very low in both studies 
(0.8%-2.2% and 3.4%-6.5%, respectively), while 
genotypes 5 and 6 were not detected[184,187].
9484 August 28, 2015|Volume 21|Issue 32|WJG|www.wjgnet.com
Vilibic-Cavlek T et al . Epidemiology of hepatitis C in Croatia
A history of blood transfusion before 1992 was 
an independent predictor of HCV infection caused 
by genotype 1[187]. Genotype 1, subtypes 1a and 1b 
were detected in majority of Croatian polytransfused 
patients with HCV infection (12%, 12% and 44%, 
respectively) (data from the Department of Infectious 
Diseases, General Hospital “Dr Josip Bencevic”, 
Slavonski Brod). In hemodialysis patients, subtype 1b 
was detected in 75% patients (33.3% received more 
than two blood transfusions) and type 3 in 20.8% 
patients[32]. Genotype 3 is predominant in Croatian 
IDUs (60.5%-83.9%)[184,185]. The most prevalent 
subtypes in this population group are 3a (60.5%) 
and 1a (23.7%)[184]. A study among Croatian male 
prisoners showed an equal distribution of genotype 
3 (52.4%) and genotype 1 (47.6%)[185]. In persons 
with high-risk sexual behavior, genotype 1 is the most 
commonly detected (55.6%) followed by genotype 
3 (38.9%). The HCV subtypes distribution is the 
following: 1a (38.9%), 3a (38.9%) and 1b (5.6%)[17].
HCV GENOTYPES DISTRIBUTION IN 
EUROPE
Understanding the HCV genotypes distribution 
is important as a part of a molecular clue for 
the spread of HCV. It is well-documented that 
genotype distribution is associated with the mode 
of transmission[4]. Available data indicate that 
genotypes 1 and 3 account for the majority of HCV 
infections in Europe. The most frequent subtype is 
1b, detected in many countries in Central (Albania, 
Bosnia and Herzegovina, the Czech Republic, Hungary, 
Montenegro, Romania), Western (Austria, France, 
Greece, Italy, Portugal, Spain) and Eastern Europe 
(Belarus, Estonia, Lithuania, Latvia and Russia) 
with a wide range of prevalences (27.2%-92.6%, 
29.7%-57.5% and 58.8%-87.7%, respectively). In 
Finland, Luxembourg, Norway and Switzerland, both 
subtypes 1b and 1a were equally prevalent, while in 
Denmark, Sweden and United Kingdom, subtype 1a 
is more commonly reported. The prevalence rates 
of genotype 3 varied from 6.6%-44.6% in Central, 
3.6%-46.0% in Western and 9.2%-38.5% in Eastern 
Europe[188]. In southern Italy, genotype 2c is commonly 
found[189,190]. Genotype 4 prevalence is rising in Europe 
(detected in significant proportions in France, Germany, 
Greece, Italy, Poland, Portugal, Spain, Sweden and 
Switzerland) reflecting immigration patterns in these 
areas[4]. Other HCV genotypes such as genotype 5 
and 6 are more geographically restricted. Genotype 
5 was found in restricted areas of Belgium, Spain, 
France and Greece and is mainly transmitted by 
blood transfusion[191]. Genotypes/subtypes 1a and 
3/3a are the most commonly identified in IDUs in 
Europe[9,138,192-196]. Genotypes 1b and 2 are linked to 
blood transfusion and unsafe medical procedures[197]. 
There are some regional differences in HCV genotypes 
among hemodialysis patients. Subtype 1b seems 
to be most frequent in the Netherlands and France 
while in Italian hemodialysis patients subtypes 2a 
and 3a predominated[198]. In the general population, 
genotypes 1 and 3 are the most commonly detected 
in majority of European countries with the prevalences 
reported to be 45.1%-79.3% and 19.7%-35.1%, 
respectively[199,200]. HCV genotype 1 is even more 
prevalent in Hungarian (85.5%) and almost exclusively 
present in Romanian (93.4%-99.1%) patients with 
chronic HCV infection[200,201]. In Italy, genotype 1b 
appears to be the most frequent (30.7%-60%), with 
genotype 2 following (21.3%-34.8%)[200]. 
FUTURE CHALLENGES
Over the past few decades, there have been remarkable 
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Figure 2  hepatitis C virus genotypes distribution in Croatia. IDU: Injecting drug users; HIV: Human immunodeficiency virus.
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changes in hepatitis C epidemiology. The prevalence 
of genotypes has evolved with time due to changes 
in the predominant route of transmission[4]. However, 
challenges in HCV prevention remain. Since IDUs 
still represent a group with the highest risk of HCV 
transmission, strategies to reduce risk among IDUs 
should be considered.
From an epidemiological point of view, one of 
the main challenges regarding HCV infection is to 
identify infected individuals in order to offer timely 
treatment. In the last five years, an average of 200 
newly discovered HCV infected persons per year are 
reported to the Reference Centre for Epidemiology, 
Croatian National Institute of Public Health. Based 
on a seroprevalence rate of 0.9% in the general 
population, we must assume that only a small part of 
the estimated 40000 Croatian HCV-positive citizens 
are aware of their HCV infection. This discrepancy 
emphasizes the need to provide testing for HCV 
infection to a larger proportion of the population.
Another challenge is to identify routes of trans-
mission in individual cases of HCV infection. In routine 
reports on surveillance of communicable diseases, the 
country is expected to report the most probable route 
of infection to WHO and to the European Centre for 
Disease Prevention and Control (ECDC). In order to 
meet these requirements, HCV infection as a reportable 
disease under enhanced surveillance, which anticipates 
collecting additional information for each case of 
HCV infection using a standardized questionnaire, in 
this case, information on the most probable route of 
infection. A large quantity of information exists on 
patients with HCV, including clinical, epidemiological, 
behavioral information, laboratory parameters, but 
is scattered among different sections of the health 
system and should be collected at one place and 
linked to an individual patient. Ideally, a registry of HCV 
infected persons should be set up, which would not only 
allow to collect and record all the relevant information 
on each individual, but would also allow monitoring 
progression of infection as well as treatment outcomes 
of patients under treatment. 
The origin of HCV is a challenge which has been 
target of virologists, epidemiologists and geneticists 
for years but has remained obscure. The majority 
of recent emerging infections in human populations 
represent zoonoses transmitted from wild animals 
and possibility of HCV cross-species transmission from 
animal species must be taken into consideration[202,203]. 
Although higher primates are susceptible to 
experimental infection, HCV naturally infects only 
humans[203]. Recently, a novel hepacivirus infecting a 
wild non-human primate, the black-and-white colobus 
(Colobus guereza), an Old world monkey from Uganda 
was discovered[204]. Animal origin of HCV is additionally 
supported by recent studies that have described related 
hepaci and pegiviruses in diverse animal species. In 
contrast to ongoing focus on primate for HCV origins, 
a virus related to HCV was described in domestic dogs 
in 2011[205]. In an effort to further investigate the host 
range of canine hepacivirus, serology-based approach 
was utilized to screen for the presence of the virus 
in mammalian species[206]. Serological evidence of 
hepacivirus infection was detected in horses with 
high prevalence while viral RNA was found in 7.8% 
seropositive horses. Equine hepacivirus (EHcV) is 
the most closely related animal hepacivirus to HCV 
described to date. Different studies confirmed EHcV 
infection in horses[207-209] and repeated sampling of 
viremic horses demonstrated viral persistence over at 
least 6-mo period and viral loads comparable to those 
observed in HCV infection[206]. Similar to HCV infections 
in humans, acute and chronic stages of EHcV infection 
in horses with viral RNA detectable predominantly 
within the liver was confirmed[210]. Several recently 
published studies demonstrated hepaciviruses and 
pegiviruses in rodents and bats[211-213]. 
Detection of multiple novel hepaciviruses in diverse 
mammalian species has highlighted the importance of 
further research to define distribution of hepaciviruses 
and their host range. Discovery of zoonotic source for 
the HCV would be an important step in understanding 
host relationship and adaptation and enhance the 
ability to study pathogenesis and immune response 
using susceptible animal models.
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